Skip directly to content

EPIPEN® AND LA RONDE HAVE TEAMED UP FOR THE 2016 SEASON

02/05/16

For immediate release

MONTREAL, May 2, 2016 – Pfizer Canada Inc., the distributor of EpiPen®, and La Ronde are pleased to announce that EpiPen® (epinephrine) Auto-Injectors are now available on the amusement park’s grounds. La Ronde, the largest amusement park in Eastern Canada, is one of the first in the country to provide epinephrine auto-injectors for guests at increased risk, or with a history, of severe allergies. The EpiPen® emergency kit will be stored at the  ark’s First Aid station and employees will be properly trained on usage.

“The safety and security of our guests and employees is our top priority,” said La Ronde President Phil Liggett. “We are pleased to provide access to an EpiPen® emergency kit in the park.”

To highlight this collaboration, EpiPen® will be holding a special day at La Ronde on Saturday, June 4. Race car driver Alex Tagliani will be onsite with his NASCAR car to meet fans, sign autographs and share his allergy management tips. Additionally, the first 50 visitors who present a valid (unexpired) EpiPen® Auto-Injector at the EpiPen® booth will receive two complimentary park tickets for a future visit. Guests who bring in two valid EpiPen® Auto-Injectors will receive a bonus baseball cap autographed by Alex Tagliani.

“Pfizer Canada is proud to partner with La Ronde, a role model in exemplifying the importance of health and safety measures at amusement parks”, adds Gerry Stefanatos, General Manager, Global Established Pharma Business, at Pfizer Canada.

“This collaboration is encouraging to those living with severe allergies”, adds Dominique Seigneur, Director of Development and Communications at Allergies Québec. “While it is important for them to take proper precautions and always carry their own epinephrine auto-injectors, having trained employees and easy access to an EpiPen® emergency kit can help provide better response in cases of a severe allergic reaction. As the mother of a child living with severe allergies, I believe this new initiative is another step in the right direction in raising awareness about allergies. We can never be too cautious despite all the precautions that are taken to avoid serious reactions.”

The Reality of Severe Allergies

It is estimated that about 7% of Canadians have food allergies[1] and that in Quebec, about 300,000 people[2] have at least one food allergy. Severe allergies are a leading cause of potentially life-threatening anaphylactic reactions and a growing public health concern [3], especially among children and adolescents. There is no way to predict how severe an allergic reaction may be and there is no known cure for anaphylaxis.

For more information about severe allergies, visit http://www.epipen.ca/en/about-severe-allergic-reactions.

About La Ronde and Six Flags

La Ronde is the property of Six Flags Entertainment Corporation, the world’s largest regional theme park company with $1.3 billion in revenue and 18 parks across the United States, Mexico and Canada. For 55 years, Six Flags has entertained millions of families with world-class coasters, themed rides, thrilling water parks and unique attractions including up-close animal encounters, and spectacular events such as Fright Fest® and Holiday in the Park®. For more information, visit sixflags.com.

About Pfizer Canada

Pfizer Canada Inc. is the Canadian operation of Pfizer Inc., one of the world's leading biopharmaceutical companies. The company is one of the largest contributors to health research in Canada. Pfizer's diversified health care portfolio includes biologic and small molecule medicines and vaccines, and many of the world's best known consumer products.

About EpiPen®

EpiPen® and EpiPen® Jr (0.3 and 0.15 mg epinephrine) Auto-Injectors (“EpiPen”) are indicated for the emergency treatment of anaphylactic reactions in patients at increased risk for anaphylaxis, including individuals with a history of anaphylactic reactions. The EpiPen® Auto-Injector is a disposable, pre-filled automatic injection device that administers epinephrine in the event of a severe allergic reaction. After using EpiPen®, you should seek immediate medical attention or go to the emergency room. For the next 48 hours, you should stay close to a healthcare facility or be able to call 911. For more information about EpiPen®, please visit www.epipen.ca or you can follow us on Facebook (facebook.com/EpiPenCanada) and YouTube (youtube.com/c/EpiPenCanada).

Important Safety Information

EpiPen® (epinephrine) Auto‐Injectors are indicated for the emergency treatment of anaphylactic reactions in patients who are determined by a physician to be at increased risk for anaphylaxis. EpiPen® (epinephrine) Auto‐Injectors are designed as emergency supportive therapy only. After administration, patients should seek medical attention immediately or go to the nearest emergency room. This product may not be right for you, always read and follow the label. For more details on EpiPen®, or educational and product safety information, please visit www.epipen.ca.

 

EpiPen®, EpiPen® Jr are registered trademarks of Mylan, Inc. licensed exclusively to its wholly-owned affiliate, Mylan Specialty L.P.; sub-licensee, Pfizer Canada Inc., Kirkland, Quebec H9J 2M5

 

-30-

For more information:

Corporate Affairs Canada
Pfizer Canada Media Line: 1-866-9Pfizer (1 866 973-4937)
[email protected]

Jules Hébert
Communications Manager, La Ronde
Tel. : 514-397-2001 x 2703
Email : [email protected]

 

 


[1] Health Canada. Food Allergies and Intolerances, http://www.hc-sc.gc.ca/fn-an/securit/allerg/index-eng.php.

[2] Statistics – Allergies Québec [in French only], http://allergies-alimentaires.org/fr/statistiques.

[3] Food Allergy Canada, Fast facts: Food Allergies in Canada, http://foodallergycanada.ca/connect-with-us/media/media-kit/.